Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 10.01%23.07B | -6.72%4.93B | 11.76%6.12B | 16.09%6.32B | 19.60%5.71B | 2.09%20.98B | 4.15%5.29B | 0.82%5.47B | 2.77%5.44B | 0.58%4.77B |
Cost of revenue | 8.27%16.5B | -6.66%3.64B | 8.15%4.34B | 12.00%4.43B | 21.27%4.09B | 10.63%15.24B | 12.37%3.9B | 8.17%4.02B | 14.57%3.95B | 7.30%3.38B |
Gross profit | 14.63%6.57B | -6.90%1.3B | 21.73%1.77B | 26.93%1.89B | 15.57%1.62B | -15.29%5.74B | -13.54%1.39B | -15.11%1.45B | -19.29%1.49B | -12.62%1.4B |
Operating expense | 1.39%4.79B | -2.98%1.13B | -6.39%1.19B | 11.06%1.31B | 4.64%1.15B | -3.94%4.73B | -13.07%1.17B | 6.84%1.27B | -1.40%1.18B | -6.98%1.1B |
Operating profit | 76.77%1.78B | -27.51%160.85M | 218.27%579.52M | 88.22%576.67M | 56.12%463.39M | -45.51%1.01B | -15.97%221.89M | -65.15%182.08M | -52.55%306.38M | -28.69%296.82M |
Net non-operating interest income (expenses) | 3.45%-3.24M | 11.03%-871K | 6.78%-715K | -2.56%-921K | -2.93%-737K | 11.51%-3.36M | -5.84%-979K | -12.63%-767K | -39.01%-898K | 53.66%-716K |
Non-operating interest income | -29.14%124K | -18.75%26K | 4.76%44K | -44.83%32K | -48.84%22K | -91.83%175K | -64.84%32K | -46.15%42K | -96.96%58K | -31.75%43K |
Non-operating interest expense | -4.72%3.37M | -11.28%897K | -6.18%759K | -0.31%953K | 0.00%759K | -40.48%3.54M | -0.49%1.01M | 6.59%809K | -62.60%956K | -52.80%759K |
Net investment income | 21.26%97.53M | 30.56%4.57M | 16.14%24.79M | 16.37%14.72M | 24.48%53.46M | 9.65%80.43M | 101.36%3.5M | 12.30%21.34M | -94.78%12.65M | -38.32%42.94M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 754.19%150.06M | ||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 2.48%-473.47M | 104.83%16.14M | 135.90%39.34M | -521.98%-70.69M | -683.16%-458.27M | -284.26%-485.53M | -224.95%-334.17M | -560.75%-109.6M | -52.02%16.75M | -162.74%-58.52M |
Less:Other special charges | -2.48%473.47M | -104.83%-16.14M | -135.90%-39.34M | 521.98%70.69M | 683.16%458.27M | 284.26%485.53M | 224.95%334.17M | 560.75%109.6M | 52.02%-16.75M | 162.74%58.52M |
Other non-operating income (expenses) | 169.10%7.57M | 545.73%14.96M | -510.19%-50.28M | 175.81%46.26M | -106.15%-3.38M | -74.64%2.81M | 44.49%-3.36M | 298.69%12.26M | -282.91%-61.02M | 646.18%54.94M |
Income before tax | 87.45%1.41B | 429.64%195.65M | 462.73%592.66M | 106.69%566.04M | -83.77%54.46M | -66.00%751.58M | -86.15%36.94M | -80.34%105.32M | -71.35%273.86M | -25.78%335.47M |
Income tax | 101.52%533.99M | 36.61%51.42M | 443.79%182.62M | 121.73%172.2M | 10.04%127.76M | -45.36%264.98M | 1.78%37.64M | -78.70%33.58M | -64.92%77.66M | 68.47%116.1M |
Net income | 79.78%874.81M | 20,823.13%144.23M | 471.61%410.04M | 100.74%393.83M | -133.41%-73.29M | -71.80%486.6M | -100.30%-696K | -81.02%71.74M | -73.29%196.19M | -42.74%219.37M |
Net income continuous operations | 79.78%874.82M | 20,793.40%144.23M | 471.60%410.04M | 100.74%393.84M | -133.41%-73.29M | -71.80%486.6M | -100.30%-697K | -81.02%71.74M | -73.29%196.19M | -42.74%219.37M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 79.78%874.81M | 20,823.13%144.23M | 471.61%410.04M | 100.74%393.83M | -133.41%-73.29M | -71.60%486.6M | -100.30%-696K | -81.02%71.74M | -73.14%196.19M | -41.56%219.37M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 79.78%874.81M | 20,823.13%144.23M | 471.61%410.04M | 100.74%393.83M | -133.41%-73.29M | -71.60%486.6M | -100.30%-696K | -81.02%71.74M | -73.14%196.19M | -41.56%219.37M |
Gross dividend payment | ||||||||||
Basic earnings per share | 78.82%76.32 | 21,016.67%12.55 | 468.84%35.78 | 99.83%34.39 | -133.26%-6.4 | -71.60%42.68 | -100.30%-0.06 | -81.03%6.29 | -73.13%17.21 | -41.56%19.24 |
Diluted earnings per share | 78.82%76.32 | 20,582.83%12.5033 | 468.80%35.7776 | 99.87%34.39 | -133.26%-6.4 | -71.60%42.68 | -100.30%-0.061 | -81.02%6.29 | -73.14%17.2064 | -41.56%19.24 |
Dividend per share | 0.00%35 | 0.00%35 | 0 | 0 | 0 | -12.50%35 | -12.50%35 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |